Abstract: A preparation method of an application of a sCAR1 mutant nanoparticle against CV-B3 infection are provided, thereby solving a problem of the current lack of preventive vaccines and specific therapeutic drugs for the CV-B3 infection. A sCAR1 Mu+Ferritin nanoparticle that fully exhibits sCAR1 Mu is constructed, and IC50 values of the sCAR1 Mu+Ferritin nanoparticle against the CV-B3 infection in Vero cells and SH-SY5Y cells are 413.05 ng/mL and 140.93 ng/mL, respectively. When 200 ?g of sCAR1 Mu+Ferritin is injected intraperitoneally 6 hours prior to an intraperitoneal injection of a lethal dose of CV-B3, it significantly reduces viral loads in liver, spleen, brain, and heart tissues, effectively alleviates inflammatory pathology in heart and brain tissues, and provides a 68.75% survival rate.

Abstract: Provided is a Coxsackievirus A6 (CVA6) strain CVA6-KM-J33 and use thereof, and belongs to the technical field of biomedicine. The present invention provides a CVA6 strain CVA6-KM-J33, which belongs to a CVA6 virus. In the present invention, the strain CVA6-KM-J33 is susceptible to KMB17 cells and can achieve a relatively high titer. The strain has strong virulence, high pathogenicity and lethality to suckling mice, and desirable immunogenicity, and is a highly effective virus strain for CVA6 vaccine development. This strain can be used for immunogenicity evaluation or protective evaluation of CVA6 vaccine to improve the accuracy and reproducibility of vaccine immunogenicity evaluation. This strain can also be used to prepare animal models of Coxsackievirus (CV) infection, and exhibits desirable application prospects.

Abstract: An enterovirus multi-antigen epitope fusion protein, a gene, a vaccine and a preparation method thereof are provided, relating to the field of vaccine preparation technologies. The amino acid sequence of the enterovirus multi-antigen epitope fusion protein is shown in SEQ ID NO: 4. The vaccine is prepared by adopting the preparation method of a genetically engineered protein vaccine, and the prepared vaccine has stronger specificity. After protein purification, there are fewer impure proteins and more specific antigen proteins, thus improving the effectiveness and safety of the combined vaccine.